4930430A15Rik Inhibitors
Proteasome inhibitors like MG-132 and Bortezomib can prevent the degradation of proteins, including potentially Potefam1, leading to their accumulation within cells. This could alter the normal turnover of Potefam1 and its associated functions. Cycloheximide acts to inhibit protein synthesis directly, which could decrease the production of Potefam1. Compounds such as LY294002, Wortmannin, and Rapamycin target various kinases that are central to intracellular signaling cascades like PI3K/AKT and mTOR, which could indirectly modulate the expression or activity of Potefam1, assuming it has a role in these pathways.
Additionally, SB203580 and PD98059 are specific inhibitors of components within the MAPK pathway, which is a key regulator of cellular responses to a variety of stimuli, and this could have implications for the function of Potefam1 if it is a MAPK-regulated protein. Trichostatin A and Sodium butyrate are histone deacetylase inhibitors that alter chromatin structure and gene transcription profiles, which could lead to changesin the expression level of Potefam1. Similarly, 5-Azacytidine can cause DNA demethylation, potentially affecting the gene expression of Potefam1.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor that can lead to the accumulation of proteins and possibly affect the turnover of Potefam1 if it is subject to ubiquitin-proteasome-mediated degradation. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Inhibits eukaryotic protein biosynthesis by interfering with translational elongation, which can decrease the synthesis of Potefam1. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that can alter AKT signaling, potentially affecting post-translational modifications or the localization of proteins such as Potefam1 if it is involved in PI3K/AKT pathway-regulated processes. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can affect protein synthesis and cell growth pathways, potentially impacting Potefam1's expression if it is regulated by mTOR signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that can modulate stress-activated protein kinase pathways, potentially affecting Potefam1's function if it is involved in these pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A MEK inhibitor that can prevent the activation of ERK, potentially influencing the expression or function of Potefam1 if it is regulated by the MAPK pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A PI3K inhibitor that, like LY294002, can affect signaling pathways that may indirectly influence Potefam1 activity or stability. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
An HDAC inhibitor that changes the acetylation status of histones, potentially affecting the transcription of genes including those that encode proteins like Potefam1. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
A DNA methyltransferase inhibitor that can lead to hypomethylation of DNA and may influence gene expression profiles, including that of Potefam1. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Another proteasome inhibitor that can affect protein degradation processes, potentially leading to an accumulation of Potefam1 if it is normally degraded through the ubiquitin-proteasome system. | ||||||